Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12561–12566 | Cite as

Antitumor activities of ginseng polysaccharide in C57BL/6 mice with Lewis lung carcinoma

  • Xiao Zhou
  • Huaiyin Shi
  • Gening Jiang
  • Yongan Zhou
  • Jianfang Xu
Research Article

Abstract

In the present study, we prepared ginseng polysaccharide (GP) and evaluated its antitumor and immunomodulatory activities in C57BL/6 mice bearing with Lewis lung carcinoma (LLC). Administration of GP (50, 100, and 200 mg/kg) could not only significantly inhibit the growth of transplantable LLC tumor in C57BL/6 mice but also remarkably increase relative weight of spleen and thymus, splenocytes proliferation, and the ratio of CD4+/CD8+ T lymphocyte in peripheral blood in LLC-bearing mice. Furthermore, the serum IL-2 and IFN-γ production and NK cytolytic activity were also prompted in LLC-bearing mice in response to GP treatment at three doses. Additionally, GP showed no side effects such as weight loss in body weight and internal organs (lung, liver, kidney, and heart) as well as inactivity during the experiment. Therefore, GP might be conveniently exploited to be good immune-stimulating modifiers and had the potential value for tumor therapy.

Keywords

Ginseng polysaccharide Antitumor Immunomodulatory 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Chang HC, Hung WC, Huang MS, Hsu HK. Extract from the leaves of Toona sinensis roemor exerts potent antiproliferative effect on human lung cancer cells. Am J Chin Med. 2002;30:307–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Ronan JK, James LG, Giuseppe G. Immunotherapy for non-small cell lung cancer. Clin Lung Cancer. 2010;11:228–37.CrossRefGoogle Scholar
  5. 5.
    Carpagnano GE, Palladino GP, Lacedonia D, Koutelou A, Orlando S, Foschino-Barbaro MP. Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8. BMC Cancer. 2011;7:226.CrossRefGoogle Scholar
  6. 6.
    Zhu W, Wang XM, Zhang L, Li XY, Wang BX. Pharmacokinetic of rhein in healthy male volunteers following oral and retention enema administration of rhubarb extract: a single dose study. Am J Chin Med. 2005;33:839–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Xiang YZ, Shang HC, Gao XM, Zhang BL. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008;22:851–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin. 2008;29:1109–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee SY, Kim YK, Il Park N, Kim CS, Lee CY, Park SU. Chemical constituents and biological activities of the berry of Panax ginseng. J Med Plants Res. 2010;5:349–53.Google Scholar
  10. 10.
    Gao QP, Kiyohara H, Cyong JC, Yamada H. Chemical properties and anti-complementary activities of polysaccharide fractions from roots and leaves of Panax ginseng. Planta Med. 1989;55:9–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang SD, Yin YX, Wei Q. Immunopotentiation on murine spleen lymphocytes induced by polysaccharide fraction of Panax ginseng via upregulating calcineurin activity. APMIS. 2010;118:288–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Staub AM. Removal of protein—Sevag method. Methods Carbohydr Chem. 1965;5:5–6.Google Scholar
  13. 13.
    Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Investig. 1999;79:1469–77.PubMedGoogle Scholar
  14. 14.
    Liang M, Li SC, Shen B, Cai JP, Li C, Wang ZY, et al. Anti-hepatocarcinoma effects of Aconitum coreanum polysaccharides. Carbohydr Polym. 2012;88:973–6.CrossRefGoogle Scholar
  15. 15.
    Liu L, Jia J, Zeng G, Zhao Y, Qi X, He C, et al. Studies on immunoregulatory and anti-tumor activities of a polysaccharide from Salvia miltiorrhiza Bunge. Carbohydr Polym. 2013;92:479–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang Y, Wang Q, Wang T, Zhang H, Tian Y, Luo H, et al. Inhibition of human gastric carcinoma cell growth in vitro by a polysaccharide from Aster tataricus. Int J Biol Macromol. 2012;51:509–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Cho WCS, Leung KN. In vitro and in vivo antitumor effects of Astragalus membranaceus. Cancer Lett. 2007;252:43–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Schepetkin IA, Quinn MT. Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol. 2006;6:317–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Aikemu A, Umar A, Yusup A, Upur H, Berké B, Bégaud B, et al. Immunomodulatory and antitumour effects of abnormal Savda Munziq on S180 tumour-bearing mice. BMC Complement Altern Med. 2012;12:157.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Li H, Sun M, Xu J, Li H, Zang M, Cui Y. Immunological response in H22 transplanted mice undergoing Aconitum coreanum polysaccharide treatment. Int J Biol Macromol. 2013;55:295–300.PubMedCrossRefGoogle Scholar
  21. 21.
    Prado-Garcia H, Aguilar-Cazares D, Flores-Vergara H, Mandoki JJ, Lopez-Gonzalez JS. Effector, memory and naïve CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer. 2005;47:361–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, et al. CD4 + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-g. Proc Natl Acad Sci U S A. 1999;96:8633–8.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Huang H, Hao S, Li F, Ye Z, Yang J, Xiang J. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology. 2007;120:148–59.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Randy RB, Venkataraman S. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol. 2002;41:287–98.CrossRefGoogle Scholar
  25. 25.
    Lehmann C, Zeis M, Uharek L. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br J Haematol. 2001;114:660–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Kim S, Lizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer activities revealed cell-deficient mice. Proc Natl Acad Sci U S A. 2000;97:2731–6.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Yamamoto N, Zou JP, Li XF, Takenaka H, Noda S, Fujii T, et al. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol. 1995;154:2281–90.PubMedGoogle Scholar
  28. 28.
    Misawa E, Sakurai T, Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK1.1+ cells in mice. Int J Immunopharmacol. 2000;22:967–77.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Thoracic Surgery, Shanghai Pulmonary HospitalMedical School of Tongji UniversityShanghaiPeople’s Republic of China
  2. 2.Department of PathologyChinese PLA General HospitalBeijingPeople’s Republic of China
  3. 3.Department of Thoracic Surgery, Tangdu Hospitalthe Fourth Military Medical UniversityXi’anPeople’s Republic of China
  4. 4.Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of MedicineTongji University Cancer InstituteShanghaiPeople’s Republic of China

Personalised recommendations